[{"orgOrder":0,"company":"LineaRx","sponsor":"EvviVax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"LinearDNA SARS-CoV-2 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LineaRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"LineaRx \/ EvviVax","highestDevelopmentStatusID":"4","companyTruncated":"LineaRx \/ EvviVax"}]

Find Clinical Drug Pipeline Developments & Deals by LineaRx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The linDNA-LNP vaccine, designed and manufactured, will be used in upcoming in vivo animal studies to assess the performance of linDNA-LNP vaccines and will inform the final design of the company’s lead veterinary asset, a linDNA-LNP canine lymphoma va...

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          July 25, 2022

                          Lead Product(s) : LinearDNA SARS-CoV-2 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : EvviVax

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank